Document Detail


Docosahexaenoic Acid Derivative Prevents Inflammation and Hyperreactivity in Lung: Implication of PKC-Potentiated Inhibitory Protein for Heterotrimeric Myosin Light Chain Phosphatase of 17 kD in Asthma.
MedLine Citation:
PMID:  21057106     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
The effects of a newly synthesized docosahexaenoic acid (DHA) derivative, CRBM-0244, on lung inflammation and airway hyperresponsiveness were determined in an in vitro model of TNF-α-stimulated human bronchi and in an in vivo model of allergic asthma. Mechanical tension measurements revealed that CRBM-0244 prevented bronchial hyperresponsiveness in TNF-α-pretreated human bronchi. Moreover, treatment with CRBM-0244 resulted in a decrease in NF-κB activation and cyclooxygenase-2 (COX-2) overexpression triggered by TNF-α. The inhibition of peroxisome proliferator-activated receptor-γ with GW9662 abolished the CRBM-0244-mediated anti-inflammatory effects. CRBM-0244 reduced the Ca(2+) sensitivity of bronchial smooth muscle through a decrease in the phosphorylation and expression of the PKC-potentiated inhibitory protein for heterotrimeric myosin light chain phosphatase of 17 kDa (CPI-17). Results also revealed an overexpression of CPI-17 protein in lung biopsies derived from patients with asthma. Furthermore, the presence of specialized enzymes such as 5-lipoxygenase and 15-lipoxygenase in the lung may convert CRBM-0244 into active mediators, leading to the resolution of inflammation. The in vivo anti-inflammatory properties of CRBM-0244 were also investigated in a guinea pig model of allergic asthma. After oral administration of CRBM-0244, airway leukocyte recruitment, airway mucus, ovalbumin-specific IgE, and proinflammatory markers such as TNF-α and COX-2 were markedly reduced. Hence, CRBM-0244 treatment prevents airway hyperresponsiveness, Ca(2+) hypersensitivity, and the overexpression of CPI-17 in lung tissue. Together, these findings provide key evidence regarding the mode of action of CRBM-0244 in the lung, and point to new therapeutic strategies for modulating inflammation in patients with asthma.
Authors:
Caroline Morin; Samuel Fortin; André M Cantin; Eric Rousseau
Related Documents :
12568486 - Post-secretory fate of host defence components in mucus.
18706396 - Curcumin attenuates ovalbumin-induced airway inflammation by regulating nitric oxide.
12162106 - The role of inflammation in the pathophysiology of cf lung disease.
20668016 - Measuring bronchitis in airway diseases: clinical implementation and application: airwa...
17599806 - Essential roles of high-mobility group box 1 in the development of murine colitis and c...
17014016 - Resistance to apoptosis in circulating alpha/beta and gamma/delta t lymphocytes from pa...
Publication Detail:
Type:  Journal Article     Date:  2010-11-05
Journal Detail:
Title:  American journal of respiratory cell and molecular biology     Volume:  45     ISSN:  1535-4989     ISO Abbreviation:  Am. J. Respir. Cell Mol. Biol.     Publication Date:  2011 Aug 
Date Detail:
Created Date:  2011-08-04     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8917225     Medline TA:  Am J Respir Cell Mol Biol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  366-75     Citation Subset:  IM    
Affiliation:
Department of Physiology and Biophysics, Faculty of Medicine and Health Sciences, Université de Sherbrooke, 3001 12th Avenue North, Sherbrooke, PQ, J1H 5N4 Canada. Eric.Rousseau@USherbrooke.ca.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Functional expression of ?-amino butyric acid transporter 2 in human and guinea pig airway epitheliu...
Next Document:  Catalytic activation of histone acetyltransferase Rtt109 by a histone chaperone.